Yingxi Intelligence and Eli Lilly reach a global pipeline licensing and AI drug development collaboration

SighingCashier · 2026-03-29T12:31:14+00:00

英矽智能 has reached a partnership with American pharmaceutical company Eli Lilly to leverage its AI technology to accelerate the development of new therapies. Eli Lilly will obtain exclusive global rights to develop new oral therapies for specific indications. 英矽智能 will receive an upfront payment of $115 million, with a total deal value of up to $2.75 billion, and will enjoy royalties from future sales.

SighingCashier

2026-03-29 12:31:14

Abstract generation in progress

Insilico Medicine (03696) has reached a licensing and drug development collaboration with Eli Lilly, where both parties will utilize Insilico’s AI pharmaceutical capabilities to accelerate the discovery and development of new therapies across multiple therapeutic areas.

According to the cooperation agreement, Eli Lilly will receive a global exclusive license for the development, production, and commercialization of a new oral therapy targeting specific indications, which is currently in preclinical development and has the potential to become a “best-in-class” treatment. Additionally, by combining Insilico’s advanced Pharma.AI platform capabilities with Eli Lilly’s extensive expertise in advancing research and disease areas, Insilico and Eli Lilly will also engage in multiple research collaborations focused on targets selected by Eli Lilly.

Under the terms of the relevant agreement, Insilico will be eligible to receive an upfront payment of $115 million and will receive further payments upon achieving development, regulatory, and commercialization milestones, bringing the total transaction value to approximately $2.75 billion; furthermore, Insilico will also receive tiered royalties based on future sales.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes